Patents Assigned to University of Iowa
  • Immunostimulatory nucleic acid molecules
    Patent number: 8158592
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: April 17, 2012
    Assignees: Coley Pharmaceutical Group, Inc., The United States of America, as represented by the Department of Health and Human Services, University of Iowa Research Foundation
    Inventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
  • MAGNETIZED BATTERY CATHODES
    Publication number: 20120088148
    Abstract: The present invention provides a magnetized cathode mixture material comprising a ferromagnetic material, an electroactive material, and an electrolyte.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 12, 2012
    Applicant: The University of Iowa Research Foundation
    Inventors: Johna Leddy, Perry Motsegood
  • Methods and devices for airway tree labeling and/or matching
    Patent number: 8155403
    Abstract: Devices, such as computer readable media, and methods, such as automated methods, for labeling and/or matching. Some of the devices and methods are particularly useful for anatomical labeling of human airway trees. Some of the devices and methods are particularly useful for matching branch-points of human airway trees from represented in two or more graphs.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: April 10, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Juerg Tschirren, Milan Sonka, Joseph Reinhardt, Geoffrey McLennan, Eric Hoffman
  • Immunomodulatory oligonucleotides
    Patent number: 8148340
    Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: April 3, 2012
    Assignees: The United States of America as represented by the Department of Health and Human Services, University of Iowa Research Foundation, Pfizer Inc.
    Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
  • Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration
    Publication number: 20120071356
    Abstract: Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided.
    Type: Application
    Filed: August 2, 2011
    Publication date: March 22, 2012
    Applicants: University of Iowa Research Foundation, National Institutes of Health, The Trustees of Columbia University in The City of New York
    Inventors: Rando L. Allikmets, Gregory S. Hageman, Michael C. Dean, Albert M. Gold
  • Isolated complexes of covalently cross-linked endotoxin and modified MD-2
    Patent number: 8137682
    Abstract: Applicants have produced and isolated chemically cross-linked complexes of endotoxin and modified MD-2, and have developed methods of using these complexes.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: March 20, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Jerrold P. Weiss, Theresa L. Gioannini
  • Immunostimulatory nucleic acid molecules
    Patent number: 8129351
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: March 6, 2012
    Assignees: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
  • Bardet-Biedl susceptibility gene and uses thereof
    Patent number: 8129161
    Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: March 6, 2012
    Assignee: The University of Iowa Research Foundation
    Inventors: Val Sheffield, Darryl Nishimura, Edwin Stone
  • Hybrid cochlear implant
    Patent number: 8126564
    Abstract: An electrode array which is able to be inserted to a desired depth within the cochlea to provide useful percepts for the recipient which will also preferably not cause damage to the sensitive structures of the cochlea. The electrode array is insertable through an opening in the cochlea and into at least the basal region of the cochlea and comprises an elongate carrier having a proximal end, a distal end, and a plurality of electrodes supported by the carrier at respective spaced locations thereon in a region between the proximal end and the distal end. A stabilising collar extends outwardly from the elongate carrier at or adjacent a proximal end thereof and has an abutment surface adapted to abut a portion of the cochlea surface around the cochleostomy and at least substantially prevent movement of the carrier following completion of insertion of the array into the cochlea.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: February 28, 2012
    Assignee: The University of Iowa
    Inventor: Bruce J. Gantz
  • Semiconductor heterostructure nanowire devices
    Patent number: 8124518
    Abstract: Nanowire devices comprising core-shell or segmented nanowires are provided. In these nanowire devices, strain can be used as a tool to form metallic portions in nanowires made from compound semiconductor materials, and/or to create nanowires in which embedded quantum dots experience negative hydrostatic pressure or high positive hydrostatic pressure, whereby a phase transitions may occur, and/or to create exciton crystals.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: February 28, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Craig Pryor, Mats-Erik Pistol
  • Increasing functional glycosylation of alpha-dystroglycan in the treatment of muscle degeneration
    Patent number: 8119766
    Abstract: Disclosed is a method for the prevention and/or treatment of muscle degeneration. In this method, a subject recognized as having muscle degeneration is treated with a composition effective to increase functional glycosylation of ?-dystroglycan in an affected tissue in the subject. Functional glycosylation is to be increased to an extent wherein the binding of ?-dystroglycan to its ligands in the affected tissue is rescued to levels substantially similar to those in an evenly matched tissue unaffected by degeneration. One effective means for increasing functional glycosylation of ?-dystroglycan in a subject includes increasing glycosyltransferase activity, such as LARGE or LARGE2 activity, in the muscle of the subject. Therapeutic glycosylated peptide compositions are also provided.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: February 21, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Kevin P. Campbell, Rita Barresi
  • Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration
    Publication number: 20120040884
    Abstract: Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm.
    Type: Application
    Filed: November 24, 2010
    Publication date: February 16, 2012
    Applicant: University of Iowa Research Foundation
    Inventor: Gregory S. Hageman
  • Immunomodulatory oligonucleotides
    Patent number: 8114848
    Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 14, 2012
    Assignees: The United States of America as represented by the Department of Health and Human Services, University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc.
    Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
  • POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES
    Publication number: 20120035320
    Abstract: The present invention provides nucleic acid delivery polyplex complexes and anionic open polyplexes comprising a nucleic acid molecule reversibly bound to one or more of nucleic acid delivery polyplex complexes.
    Type: Application
    Filed: April 4, 2011
    Publication date: February 9, 2012
    Applicant: University of Iowa Research Foundation
    Inventors: Kevin G. Rice, Nicholas J. Baumhover, Christian A. Fernandez, Kevin Anderson, Mark D. Ericson, Jason T. Duskey, Koby Kizzire, Sanjib Khargharia, Samuel T. Crowley
  • SYNTHESIS OF HIERARCHICAL NANOCRYSTALLINE ZEOLITES WITH CONTROLLED PARTICLE SIZE AND MESOPOROSITY
    Publication number: 20120027673
    Abstract: A one step synthesis of nanocrystalline zeolites ZSM-5 and Na? from a single template system in high yield has been discovered. The size of individual nanocrystals, as well as mesopore surface area and pore volume can be controlled by adjusting the pH of the reaction mixture, as well as the hydrothermal treatment temperature and duration. The mesopore volume and size distribution show a dependence on particle size such that smaller particles lead to higher mesopore volumes and narrower pore size distributions.
    Type: Application
    Filed: July 28, 2011
    Publication date: February 2, 2012
    Applicant: University of Iowa Research Foundation
    Inventors: Sarah Larsen, Anton Petushkov
  • NUCLEIC ACID APTAMERS
    Publication number: 20120014875
    Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.
    Type: Application
    Filed: August 6, 2009
    Publication date: January 19, 2012
    Applicant: University of Iowa Research Foundation
    Inventors: Paloma H. Giangrande, James O. McNamara, Anton P. McCaffrey
  • Systems and methods for bioluminescent computed tomographic reconstruction
    Patent number: 8090431
    Abstract: An image of an object is synergistically reconstructed using two or multiple imaging modalities. A first reconstructed image, showing structural information of the object is produced using a first imaging modality. The first reconstructed image is segmented, and known optical properties of the object are then mapped to the first reconstructed image. Optical signal emissions from the object are detected and registered with the first reconstructed image. A second reconstructed image volume is then produced using a second imaging modality, based on the mapped optical properties after registration between the first image and the data from the second modality. The second reconstructed image depicts some optical property, such as a bioluminescent source distribution, or optical properties, such as, attenuation and scattering properties, of the object.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: January 3, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Ge Wang, Eric Hoffman, Geoffrey McLennan
  • Complement factor H for diagnosis of age-related macular degeneration
    Patent number: 8088579
    Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: January 3, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Gregory S. Hageman, Richard J. Smith
  • Isolated complexes of endotoxin and modified MD-2
    Patent number: 8088396
    Abstract: Applicants have produced and isolated water soluble complexes of endotoxin and modified MD-2.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: January 3, 2012
    Assignee: University of Iowa Research Foundation
    Inventor: Jerrold P. Weiss
  • REGULATION OF THE SEROTONIN REUPTAKE TRANSPORTER AND DISEASE
    Publication number: 20110318735
    Abstract: Described herein is a CpG island in the 5? region of the 5HTT gene that contains an alternative exon 1 and promoter for 5HTT. Methylation at this CpG island is associated with decreased levels of 5HTT mRNA, and this effect is evident when 5HTTLPR genotype is taken into account. Thus, this methylation status indicates 5HTT mRNA production, which serves as an indicator for the expression of the transporter and of a subject's vulnerability to diseases related to serotonergic activity. Accordingly, certain embodiments of the present invention provide diagnostic methods for determining whether a subject has, or is at risk for developing, a disease associated with serotonergic activity.
    Type: Application
    Filed: April 15, 2011
    Publication date: December 29, 2011
    Applicant: University of Iowa Research Foundation
    Inventors: Robert Philibert, Anup Madan